News & Events

MARCH 20, 2020

GammaTile: New Approach For The Treatment Of Brain Tumors. Watch here

MARCH 9, 2020

GT Medical Technologies Named as "Fierce 15" Company of 2019 by FierceMedTech. Read more

JANUARY 27, 2020

GT Medical Technologies Announces FDA Clearance of Expanded Indication for GammaTile Therapy. 
Read more

JANUARY 22, 2020

Vidant, ECU Brody School of Medicine successfully perform first-in-state GammaTile procedure.

Watch here

JANUARY 1, 2020

2019 Year In Review by President & CEO Matt Likens. Read here

DECEMBER 27, 2019

Menorah Medical Center performs new brain surgery in Kansas. Watch here

NOVEMBER 10, 2019

What's Happening in Health: Liz Bonis is joined by a team to talk about brain tumor surgery. Watch here

OCTOBER 21, 2019

Battling Brain Tumors With Time-Released Radiation. Watch here

OCTOBER 11, 2019

Fighting Tumors With Brain Implants. El Camino Doctors Turn To Radiation "Tiles" In The Fight Against Recurring Brain Tumors. Read here

OCTOBER 1, 2019

El Camino Health First on West Coast to Offer New Targeted Therapy for Recurrent Brain Tumors.

Read here

SEPTEMBER 18, 2019

Arizona: The New Frontier in Technology and Health Care. Read here

AUGUST 26, 2019

GT Medical Technologies, Inc. to Be Honored With an AZBio Fast Lane Award. Read here

AUGUST 20, 2019

Mayfield Brain and Spine neurosurgeon using new radiation therapy in Ohio. View video

AUGUST 15, 2019

GT Medical Technologies announces completion of first case in Arizona using GammaTile Therapy. 

Read here

AUGUST 14, 2019

New therapy to slow down brain tumors forever changes Arizona woman's life. View video

GT Medical Technologies announces the presentation of data demonstrating the safety profile of GammaTile Therapy for various brain tumors. 

JUNE 17, 2019

JUNE 11, 2019

GT Medical Technologies is a Tempe-based company that has created a new way to target brain tumors, like the type that took the late Senator John McCain’s life.  Watch the interview with Dr. David Brachman, Co-Founder and Chief Technology Officer of GT Medical Technologies, to learn more. View video

Surgically Targeted Radiation Therapy: A Prospective Trial in 79 Recurrent, Previously Irradiated Intracranial Neoplasms. A presentation at the 2019 American Association of Neurological Surgeons Annual Scientific Meeting. 

APRIL 15, 2019

GT Medical Technologies co-founder to receive prestigious Rosenblum-Mahaley Clinical Research Award at 2019 American Association of Neurological Surgeons annual scientific meeting.

APRIL 11, 2019

Tempe-based medical tech startup improving recovery for brain tumor patients.

APRIL 8, 2019

Doctors at the University of Minnesota are the first in the country to use a breakthrough brain cancer treatment.

FEBRUARY 14, 2019

University of Minnesota is the first in the U.S. to offer GammaTile Therapy, a new targeted therapy for recurrent brain tumors. 

FEBRUARY 14, 2019

GT Medical Technologies, Inc. announces $10 million financing to support launch of targeted therapy for patients with recurrent brain tumors.

JANUARY 31, 2019

JANUARY 3, 2019

GT announces clinical trial results and accompanying publication in the Journal of Neurosurgery (JNS).  

News Archive


JULY 6, 2018
The US Food and Drug Administration provides notice of 510(k) clearance of GammaTile Therapy in the treatment of recurrent intracranial neoplasms.

MARCH 15, 2018
GT Medical Technologies, Inc. is selected as the winner of the MedTech Innovator Accelerator regional pitch competition in San Francisco.

MARCH 8, 2018
GT Medical Technologies, Inc. is selected to participate in MedTech Innovator Accelerator regional pitch competition in San Francisco on March 15th, 2018.

FEBRUARY 22, 2018
GT Medical Technologies, Inc. is selected for the 2018 Flinn Foundation entreprenuership program.

JANUARY 8, 2018
GT Medical Technologies, Inc. announces the signing of a manufacturing and supply agreement with IsoRay Medical.

JANUARY 31, 2018
GT Medical Technologies, Inc. completes its final round of seed financing, totaling nearly $3 million. MTVP was joined by angel groups Arizona Technology Investors (ATI), Desert Angels, and Grand Canyon Angels in addition to several high-net-worth individuals.


DECEMBER 29, 2017 GT Medical Technologies, Inc. completes its first round of seed financing, led by MedTech Venture Partners (MTVP) of San Francisco. DECEMBER 20, 2017 GT Medical Technologies, Inc. is named as an awardee of the fall 2017 Arizona Innovation Challenge by the Arizona Commerce Authority, earning $250,000 in nondilutive growth capital.


GammaTile Therapy is intended to deliver radiation therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). Serious side effects related to GammaTile Therapy are rare, and may include radiation brain changes including necrosis. GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2020 GT Medical Technologies, Inc. I All rights reserved | Privacy Policy | Terms of Use